# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lou Gehrig (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET018-SYN-TD
- Date: 1939-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gavin Hollister, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six weeks after diagnosis: riluzole safety, genetic test result, the ALS clinic plan, mobility, mood, and work. **S**

## History of present illness

Mr. Gehrig returns six weeks after the diagnosis, a week after his first full visit to the multidisciplinary ALS clinic, where he saw the physical, occupational and speech therapists, the dietitian, the respiratory therapist and the social worker. He has taken riluzole twice daily; he had mild nausea in the first week, which settled. The genetic panel found no disease-causing variant in SOD1, C9orf72, FUS, TARDBP or the other genes tested. His grip is weaker and he has tripped twice without falling; the clinic measured him for a left ankle-foot orthosis. He has decided to stop playing professionally and plans to say so publicly soon, and he is thinking about work he could do at a desk. He has been sleeping poorly and feels low at times but enjoys time with friends. **S**

| Element | Detail |
|---|---|
| Riluzole | Twice daily; nausea in the first week, settled |
| Genetic testing | No disease-causing variant found |
| Function | Grip weaker; two trips without a fall; orthosis measured |
| Work | Decided to stop playing; considering desk work |
| Mood | Low at times; poor sleep |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Weaker grip; left foot catching; cramps at night |
| Ears, nose, mouth, and throat | Negative | No slurred speech or choking |
| Respiratory | Negative | No breathlessness or orthopnea |
| Gastrointestinal | Negative | Nausea gone; appetite good |
| Psychiatric | Positive | Low at times; poor sleep; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Riluzole 50 mg oral tablet, one tablet by mouth twice daily, an hour before or two hours after meals **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 72 bpm; respirations 15/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 88.4 kg; BMI 26.4 kg/m². All vital signs are synthetic.

ALT: 38 U/L; AST: 33 U/L; Forced vital capacity (seated): 4.31 L; Forced vital capacity, percent predicted (seated): 84%; ALSFRS-R total (0 to 48): 40; PHQ-9: 8. All results are synthetic.

## Change since baseline

- ALT: 32 U/L at baseline, 38 U/L at this visit **S**
- AST: 30 U/L at baseline, 33 U/L at this visit **S**
- Forced vital capacity (seated): 4.62 L at baseline, 4.31 L at this visit **S**
- Forced vital capacity, percent predicted (seated): 90% at baseline, 84% at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 120/76, pulse 72; weight 88.4 kg |
| Neurological | Hand wasting slightly more marked; grip 4-/5 on both sides; left ankle dorsiflexion 4-/5; fasciculations in the arms and legs; reflexes brisk; tongue normal |
| Gait | Left foot slap; steady with a hand on the rail |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Amyotrophic lateral sclerosis, limb onset** (G12.21). Slow progression: ALSFRS-R 40 (42 at diagnosis), FVC 4.31 L (84%), maximal inspiratory pressure -80 cmH2O, weight 88.4 kg (0.9% below diagnosis). ALT 38 and AST 33 U/L on riluzole. No SOD1 variant, so tofersen does not apply; no family history of ALS is known. The one-month liver test was missed and is recorded as a protocol deviation. **S**
   - Continue riluzole; ALT at two and three months.
   - Left ankle-foot orthosis and a cane for outdoors; home exercise plan; button hook and adapted cutlery.
   - High-calorie diet; gastrostomy explained early, while breathing is strong.
   - Voice banking introduced by the speech therapist.
   - Workplace accommodations and disability benefits with the social worker.
2. **Coping with ALS and leaving professional play**. PHQ-9 8 (mild); no thoughts of self-harm. Grief at leaving the game; good supports. **S**
   - Sessions with the ALS clinic psychologist.
   - Sleep advice; review at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | ALSFRS-R | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | 40 of 48 (42 at diagnosis) |
| Imaging | Seated forced vital capacity | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | 4.31 L, 84% of predicted |
| Examination | Maximal inspiratory pressure; supine capacity and overnight oximetry when values fall or symptoms appear | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | Maximal inspiratory pressure -80 cmH2O; no orthopnea |
| Examination | Noninvasive ventilation criteria (FVC below 50%, maximal inspiratory pressure weaker than -60 cmH2O, nocturnal desaturation, orthopnea) | Every 2 to 3 months in the multidisciplinary ALS clinic | Not indicated | No criterion met |
| Examination | Weight and BMI (gastrostomy discussion if weight falls 5 to 10% or swallowing is unsafe; place while FVC is above 50%) | Every visit | Completed today | 88.4 kg, 0.9% below diagnosis |
| Examination | Speech and swallowing assessment | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | Normal at the clinic speech assessment; voice banking introduced |
| Survey | Depression (PHQ-9) | Every visit | Completed today | PHQ-9 8, mild |
| Examination | Symptoms: cramps, spasticity, saliva, emotional lability, pain | Every visit | Completed today | Night cramps, eased by stretching; no spasticity problems, drooling or emotional lability |
| Examination | Mobility, falls, orthoses and equipment | Every visit | Completed today | Foot drop; orthosis measured; cane advised |
| Laboratory | ALT on riluzole | Monthly for 3 months, then every 3 months | Deferred | Missed: no liver test was drawn at one month because no visit fell then. ALT 38 U/L today, at six weeks, is normal, so no harm resulted. Corrective action: two- and three-month tests booked with the ALS clinic laboratory |
| Laboratory | Genetic testing (SOD1 result decides tofersen) | Offer at diagnosis to every person with ALS | Completed today | No disease-causing variant in SOD1, C9orf72, FUS, TARDBP or the other genes tested; tofersen not indicated |
| Referral | Multidisciplinary ALS clinic | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | First full clinic visit last week |
| Self-management | Work, disability benefits and social work | From diagnosis | Completed today | Stopping professional play; exploring desk work and benefits with the social worker |
| Self-management | Advance care planning | Early, then at each change | Due | Planned for the preventive visit, at his choice |

## Goal progress

- A clear diagnosis, with mimics excluded, within four weeks. Outcome by 1939-05-18: Diagnosis made at two weeks on EMG, MRI and blood tests. **S**
- No falls, using an ankle-foot orthosis, a cane, and a safer home. In progress; target 1939-10-19. **S**
- Weight held within 5% of the weight at diagnosis. In progress; target 1939-10-19. **S**
- Breathing tracked every visit, with noninvasive ventilation started as soon as criteria are met. In progress; target 1939-10-19. **S**
- Goals of care, a health care agent, and his wishes about ventilation and feeding recorded early and revisited. In progress; target 1939-09-21. **S**
- Working in a role that suits him, with accommodations. In progress; target 1939-10-19. **S**

## Guideline basis

- Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review) (2009), American Academy of Neurology (Neurology)
- Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) (2009), American Academy of Neurology (Neurology)
- Evidence-based consensus guidelines for ALS genetic testing and counseling (2023), Annals of Clinical and Translational Neurology
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (2022), New England Journal of Medicine

## Follow-up

- Liver tests at two and three months. ALS clinic in about two months, with primary care the same week. **S**
- Next scheduled visit 1939-08-24: three months after diagnosis: ALSFRS-R, breathing, weight, speech, mobility equipment, and work accommodations. **S**
